Atherosclerosis ischemic stroke
Conditions
Interventions
non-aspirin resistance:oral aspirin or change other antiplatelet strategy
aspirin resistance:oral aspirin or change other antiplatelet strategy
CC and CT group:oral aspirin or change other antiplatelet strategy
control group (TT group):oral aspirin or change other antiplatelet strategy
Sponsors
Lanzhou General Hospital of Lanzhou Military Area Command
Eligibility
Sex/Gender
All
Age
45 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. aged 45 years old and more; 2. Patients who had been diagnosed atherosclerosis ischemic stroke must have had a recurrent stroke which defines transient ischemia attach(TIA), ischemic stroke or silence stroke. Magnetic resonance/computerized tomography can find the new ischemic Lesions; 3. Have taken aspirin for more than 24 hours; 4. All subjects must be volunteers and willing to sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Acute cerebral ischemic events is deriving from non- atherosclerosis ischemic stroke(Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria (II, IV, V)); 2. Subjects with the symptoms of neurological impairment without evidence of acute infarction on baseline CT or MRI of the head; 3. Exclude below diseases such as intracerebral hemorrhage, vascular malformation, tumor, abscess and so on; 4. Subjects with documented history of any gastrointestinal disorders or other organs bleeding or major surgery within the previous 3 months; 5. Subjects with any coagulation, bleeding or blood disorders; 6. Subjects, who have received heparin therapy, oral anticoagulation therapy or other antiplatelet drugs before randomization; 7. Subjects who have had treatment with thrombolysis around the time of randomization; 8. Subjects who have had endovascular stent in cervical or intracranial artery and oral dual antiplatelet drugs before randomization; 9. Subjects who are contraindicated in aspirin as well as any of their components.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| glycoprotein IIIa polymorphism;Platelet aggregation rate;recurrent ischemic stroke;intracerebral hemorrhage;mortality rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| NIHSS;brain CT or MRI; | — |
Countries
China
Contacts
Public ContactRong Yin
Department of Neurology, Lanzhou General Hospital of Lanzhou Military Area Command
Outcome results
None listed